While Nautilus Biotechnology Inc has underperformed by -1.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAUT fell by -16.07%, with highs and lows ranging from $2.92 to $0.62, whereas the simple moving average jumped by 46.01% in the last 200 days.
On December 05, 2024, Goldman Downgraded Nautilus Biotechnology Inc (NASDAQ: NAUT) to Sell. A report published by Guggenheim on June 27, 2024, Initiated its previous ‘Buy’ rating for NAUT. Jefferies also rated NAUT shares as ‘Hold’, setting a target price of $3 on the company’s shares in an initiating report dated June 03, 2024. Morgan Stanley Initiated an Equal-Weight rating on January 06, 2022, and assigned a price target of $8. Cowen initiated its ‘Outperform’ rating for NAUT, as published in its report on November 02, 2021. Goldman’s report from August 04, 2021 suggests a price prediction of $10 for NAUT shares, giving the stock a ‘Neutral’ rating. Jefferies also rated the stock as ‘Buy’.
Analysis of Nautilus Biotechnology Inc (NAUT)
In order to gain a clear picture of Nautilus Biotechnology Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -32.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 14.95, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 408.62K can be a very valuable indicator of volatility for NAUT stock. On a monthly basis, the volatility of the stock is set at 14.10%, whereas on a weekly basis, it is put at 19.24%, with a gain of 11.90% over the past seven days. Furthermore, long-term investors anticipate a median target price of $2.50, showing growth from the present price of $1.41, which can serve as yet another indication of whether NAUT is worth investing in or should be passed over.
How Do You Analyze Nautilus Biotechnology Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 52.75%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 27.39% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
